Ionis to present at the Cowen Annual Health Care Conference
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/12/2026
- Nasdaq falls ahead of earnings, economic data while oil rallies
- Oil prices rise on Saudi Arabia attacks, overshadowing Trump's diesel deal
- Will surging equity supply derail the U.S. bull market? Goldman Sachs weighs in
- Broadcom CEO says many AI investors are gamblers
- "Not buying Chipotle": Starbucks squashes blockbuster acquisition speculation
- One dead in new attack on Saudi airport, a day after Houthi strike kills 13
- Bausch + Lomb names Appio interim CEO as Saunders departs
- Cerebras Systems hits new 52-week low on unlock concerns
- Getty Images to go private via prepackaged Chapter 11 restructuring
- Lumentum shares fall after hitting 52-week high
Guggenheim Starts Ionis Pharmaceuticals (IONS) at Buy
March 1, 2022 8:18 AM ESTGuggenheim analyst Debjit Chattopadhyay initiates coverage on Ionis Pharmaceuticals (NASDAQ: IONS) with a Buy rating and a price target of $64.00.
The analyst commented, "We are initiating coverage of IONS with a BUY rating. While the platform has had its fair share... More



